Inventor · disambiguated record
Roselyne Castonguay
Also filed as: CASTONGUAY ROSELYNE
33 granted patents·21 pending applications·70 citations·filing 2012–2025
96Inventor score
Top patents by PatentIndex Score
54 records- 0196US9809637B2Transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2016·Granted Nov 7, 2017·19 cites·9 claims
- 0293US11028145B2ALK7:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jun 8, 2021·4 cites·23 claims
- 0393US10227393B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·9 cites·27 claims
- 0491US11279746B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Granted Mar 22, 2022·2 cites·11 claims
- 0591US10738098B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2018·Granted Aug 11, 2020·6 cites·33 claims
- 0690US10501547B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2017·Granted Dec 10, 2019·3 cites·7 claims
- 0789US10906958B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Feb 2, 2021·2 cites·4 claims
- 0887US10307455B2Activin type 2 receptor antibodiesACCELERON PHARMA INC·Filed 2017·Granted Jun 4, 2019·5 cites·14 claims
- 0987US2024158468A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2023·Application pending·0 cites
- 1086US10316076B2Transforming growth factor-beta receptor type II fusion polypeptidesACCELERON PHARMA INC·Filed 2017·Granted Jun 11, 2019·3 cites·19 claims
- 1186US10227392B2ALK7:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·3 cites·29 claims
- 1286US10196434B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Feb 5, 2019·3 cites·31 claims
- 1385US2024374671A1Activin Type 2 Receptor Binding Proteins and Methods of Making ThemACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 1484US11951156B2Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptorBRIGHAM & WOMENS HOSPITAL INC·Filed 2020·Granted Apr 9, 2024·1 cites·17 claims
- 1584US2025368720A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2025·Application pending·0 cites
- 1684US2024309098A1Alk7 antagonists and uses thereofACCELERON PHARM INC·Filed 2024·Application pending·0 cites
- 1783US11059894B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jul 13, 2021·1 cites·7 claims
- 1883US10682392B2Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion proteinBRIGHAM & WOMENS HOSPITAL INC·Filed 2014·Granted Jun 16, 2020·4 cites·11 claims
- 1982US12258380B2ALK4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2022·Granted Mar 25, 2025·0 cites·20 claims
- 2082US2023416379A1ALK7 Binding Proteins and Uses ThereofACCELERON PHARMA INC·Filed 2023·Application pending·0 cites
- 2180US11440949B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2017·Granted Sep 13, 2022·1 cites·15 claims
- 2279US12421295B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2022·Granted Sep 23, 2025·0 cites·11 claims
- 2379US2025197469A1Alk4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2025·Application pending·0 cites
- 2478US12024563B2ALK7 antagonists and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Jul 2, 2024·0 cites·12 claims
- 2578US11827689B2ALK7:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Nov 28, 2023·0 cites·21 claims
- 2678US9932386B2Endoglin polypeptides and uses thereofGRINBERG ASYA·Filed 2012·Granted Apr 3, 2018·3 cites·25 claims
- 2778US2024366720A1Compositions and methods for treating pulmonary hypertensionBRIGHAM & WOMENS HOSPITAL INC·Filed 2024·Application pending·0 cites
- 2877US11708414B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Jul 25, 2023·0 cites·7 claims
- 2977US10981972B2Endoglin polypeptides and uses thereofACCELERON PHARMA INC·Filed 2018·Granted Apr 20, 2021·1 cites·11 claims
- 3077US2025084388A1Alk4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 3176US12042524B2Activin type 2 receptor binding proteins methods of making themACCELERON PHARMA INC·Filed 2021·Granted Jul 23, 2024·0 cites·15 claims
- 3276US2021230252A1Tgf-beta receptor type ii variants and uses thereofACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 3375US2024287196A1ALK7 Binding Proteins and Uses ThereofACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 3474US2022396607A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 3574US2025333477A1Novel binders of tgfb-superfamily ligands and uses thereofACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 3673US11008377B2Methods of treating a fibrotic disorder by administering transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2020·Granted May 18, 2021·0 cites·16 claims
- 3773US10981973B2Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptideACCELERON PHARMA INC·Filed 2019·Granted Apr 20, 2021·0 cites·17 claims
- 3873US2025109179A1MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOFACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 3971US11000565B2Methods of increasing muscle mass by administration of activin type 2 receptor antibodiesACCELERON PHARMA INC·Filed 2019·Granted May 11, 2021·0 cites·10 claims
- 4069US12054753B2Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimersACCELERON PHARMA INC·Filed 2020·Granted Aug 6, 2024·0 cites·19 claims
- 4168US2021300991A1Endoglin polypeptides and uses thereofACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 4267US11590201B2Endoglin peptides to treat fibrotic diseasesACCELERON PHARMA INC·Filed 2019·Granted Feb 28, 2023·0 cites·16 claims
- 4367US2019218272A1Alk4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 4465US2015056199A1Tgf-beta receptor type ii variants and uses thereofACCELERON PHARMA INC·Filed 2014·Application pending·0 cites
- 4563US2020048355A1Alk7 antagonists and uses thereofACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 4661US11981738B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2018·Granted May 14, 2024·0 cites·11 claims
- 4760US10934532B2ALK4.ActRIIB heteromultimersACCELERON PHARMA INC·Filed 2017·Granted Mar 2, 2021·0 cites·1 claims
- 4858US12103959B2Multispecific binders of TGFBeta-superfamily ligands and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Oct 1, 2024·0 cites·8 claims
- 4958US2015202260A1Endoglin peptides to treat fibrotic diseasesACCELERON PHARMA INC·Filed 2014·Application pending·0 cites
- 5057US12168683B2Binders of TGFβ-superfamily ligands and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Dec 17, 2024·0 cites·14 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Roselyne Castonguay files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →